人類胰島素製劑市場按產品類型、應用和地區分類

2025 年全球人類胰島素製劑市場規模估計為 570.4 億美元，預計到 2032 年將達到 1,023.5 億美元，2025 年至 2032 年的複合年成長率為 8.7%。

數字。 2025 年人類胰島素製劑市場佔有率（按地區分類）

由於全球糖尿病盛行率不斷上升，過去幾年全球人類胰島素製劑市場一直穩定成長。人類胰島素製劑是常規人類胰島素的生物合成版本，用於治療和控制糖尿病。根據國際糖尿病聯盟發布的資料，2020年全球約有4.63億成年人患有糖尿病，預計2045年將上升至7億。糖尿病患者數量的增加、人們對胰島素治療認知的提高以及胰島素筆和胰島素幫浦等創新胰島素輸送系統的推出，預計將推動全球對人類胰島素製劑的需求。

市場動態

全球人類胰島素製劑市場的成長主要受到肥胖、久坐的生活方式、人口老化和遺傳因素導致的糖尿病盛行率不斷上升的推動。根據世界衛生組織統計，糖尿病是主要死亡原因之一，估計每年有150萬人死於糖尿病。人們對胰島素治療的認知不斷提高，以及胰島素幫浦和胰島素筆等各種創新的胰島素給藥方式，可能會推動市場成長。然而，人類胰島素製劑的高成本可能會阻礙市場的成長。生物相似藥人類胰島素製劑的開發為市場參與企業帶來了豐厚的成長機會。

研究的主要特點

• 本報告對全球人類胰島素製劑市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 全球人類胰島素製劑市場的主要企業已根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行了分析。
• 主要企業包括賽諾菲、諾和諾德 A/S、Biocon Limited、輝瑞公司、禮來公司、Wockhardt Ltd.、SEDICO、Exir、Aventis、默克公司、Julphar、GLENMARK PHARMACEUTICALS LTD.、勃林格格翰國際有限公司和殷邁蘭公司。
• 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
• 全球人類胰島素製劑市場迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 可以透過分析全球人類胰島素製劑市場所使用的各種策略矩陣來促進相關人員的決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖 (COM)

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管情景
• 製造商收益
• 收購和合作場景
• 產品發布/核准
• 資金籌措和投資
• PEST分析
• 波特的分析

4. 全球人類胰島素製劑市場-冠狀病毒（COVID-19）大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

5. 2020-2032 年全球人類胰島素製劑市場（按產品類型分類）（十億美元）

• 介紹
• 人類胰島素
• 基礎胰島素
• Bolus胰島素
• 混合胰島素
• 生物相似藥胰島素

6. 2020 年至 2032 年全球人類胰島素製劑市場（按類型分類）（十億美元）

• 介紹
• 短效
• 長效

7. 2020 年至 2032 年全球人類胰島素製劑市場（按應用分類）（十億美元）

• 介紹
• 1 型糖尿病
• 2 型糖尿病

8. 2020 年至 2032 年全球人類胰島素製劑市場（按地區分類）（十億美元）

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan NV

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Human Insulin Drug Market is estimated to be valued at USD 57.04 Bn in 2025 and is expected to reach USD 102.35 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Figure. Human Insulin Drug Market Share (%), By Region 2025

Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2020 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.

Market Dynamics:

Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global human insulin drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human insulin drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this includes Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis , Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human insulin drug market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market

Detailed Segmentation-

• By Product Type:
  • Human Insulin
  • Basal Insulin
  • Bolus Insulin
  • Insulin Combinations
  • Biosimilar Insulins
• By Type:
  • Short Acting
  • Long Acting
• BY Application:
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Human Insulin Drug Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Human Insulin Drug Market, By Product Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Human Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Basal Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bolus Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Insulin Combinations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biosimilar Insulins
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Human Insulin Drug Market, By Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Short Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Long Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Human Insulin Drug Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Type 1 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Type 2 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Human Insulin Drug Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Forecast, and Y-o-Y Growth, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Sanofi*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biocon Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wockhardt Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SEDICO
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Exir
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aventis
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan N.V.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact